Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – A population-based cohort study
出版年份 2015 全文链接
标题
Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – A population-based cohort study
作者
关键词
-
出版物
ACTA ONCOLOGICA
Volume 55, Issue 3, Pages 265-277
出版商
Informa UK Limited
发表日期
2016-02-17
DOI
10.3109/0284186x.2015.1068445
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study
- (2014) Juan W. Valle et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
- (2014) Henriette Golcher et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Postoperative Complications Reduce Adjuvant Chemotherapy Use in Resectable Pancreatic Cancer
- (2013) Ryan P. Merkow et al. ANNALS OF SURGERY
- Impact of Adjuvant Radiotherapy on Survival after Pancreatic Cancer Resection: An Appraisal of Data from the National Cancer Data Base
- (2013) David A. Kooby et al. ANNALS OF SURGICAL ONCOLOGY
- Adjuvant chemotherapy in elderly patients with pancreatic cancer
- (2013) A M Nagrial et al. BRITISH JOURNAL OF CANCER
- Pancreatoduodenectomy associated complications influence cancer recurrence and time interval to death
- (2013) N.A. van der Gaag et al. EJSO
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival
- (2013) Ching-Wei D. Tzeng et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Severe Postoperative Complications Adversely Affect Long-Term Survival After R1 Resection for Pancreatic Head Adenocarcinoma
- (2013) David Petermann et al. WORLD JOURNAL OF SURGERY
- Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy
- (2012) Ching-Wei D. Tzeng et al. ANNALS OF SURGICAL ONCOLOGY
- Resection margin involvement and tumour origin in pancreatic head cancer
- (2012) C. S. Verbeke et al. BRITISH JOURNAL OF SURGERY
- Reclassification of tumour origin in resected periampullary adenocarcinomas reveals underestimation of distal bile duct cancer
- (2012) E. Pomianowska et al. EJSO
- Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma
- (2012) Yoshiaki Murakami et al. JOURNAL OF SURGICAL ONCOLOGY
- A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma
- (2012) Russell Lewis et al. HPB
- Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades
- (2011) Jordan M. Winter et al. ANNALS OF SURGICAL ONCOLOGY
- Postoperative Complications Deteriorate Long-Term Outcome in Pancreatic Cancer Patients
- (2011) Carsten Kamphues et al. ANNALS OF SURGICAL ONCOLOGY
- Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery
- (2011) G. A. Gooiker et al. BRITISH JOURNAL OF SURGERY
- A Systematic Review and Meta-analysis of Survival and Surgical Outcomes Following Neoadjuvant Chemoradiotherapy for Pancreatic Cancer
- (2011) Jerome Martin Laurence et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Management of Patients with Pancreatic Adenocarcinoma: National Trends in Patient Selection, Operative Management, and Use of Adjuvant Therapy
- (2011) Skye C. Mayo et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study
- (2010) Charles C. Hsu et al. ANNALS OF SURGICAL ONCOLOGY
- Progress for resectable cancer?
- (2010) Jessica P. Simons et al. CANCER
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pancreatic surgery: Evolution at a high-volume center
- (2010) Kathryn M. Ziegler et al. SURGERY
- Impact of Selection Bias on the Utilization of Adjuvant Therapy for Pancreas Adenocarcinoma
- (2009) Andrew J. Russ et al. ANNALS OF SURGICAL ONCOLOGY
- Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma
- (2009) Matthew H. G. Katz et al. ANNALS OF SURGICAL ONCOLOGY
- A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
- (2009) H Ueno et al. BRITISH JOURNAL OF CANCER
- Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients
- (2009) Halfdan Sorbye et al. CANCER
- Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma
- (2009) A. Van den broeck et al. EJSO
- Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma
- (2008) William F. Regine et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More